Cannabis ETF Carnage: Only 3 Funds Survive Industry Meltdown
Most cannabis ETFs have shuttered as the sector collapsed, leaving just three funds trading amid widespread investor exodus and performance disasters.
The cannabis ETF landscape has become a graveyard, with only three exchange-traded funds remaining operational after a wave of closures decimated the sector. What once promised diversified exposure to the emerging cannabis industry has delivered catastrophic losses, forcing fund managers to shutter products that attracted billions in early investor enthusiasm.
The surviving funds face mounting pressure as cannabis stocks continue their multi-year decline. The AdvisorShares Pure US Cannabis ETF (MSOS) remains the largest with approximately $400 million in assets, down from peak levels exceeding $1.5 billion. The Global X Cannabis ETF (POTX) and ETFMG Alternative Harvest ETF (MJ) round out the remaining options, each managing substantially reduced asset bases as institutional and retail investors fled.
Fund closures accelerated as performance metrics turned toxic across the sector. Cannabis ETFs that launched during 2018-2021 hype cycles delivered losses exceeding 80% from peak valuations, triggering automatic closure mechanisms when assets fell below viable operating thresholds. The exodus reflects broader structural problems plaguing cannabis equities, including federal prohibition constraints, oversupply issues, and compressed margins across cultivation and retail operations.
Remaining ETFs concentrate holdings in multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF), creating concentrated exposure to companies struggling with declining revenues and profitability challenges. These operators face intensifying competition as state markets mature while federal banking restrictions continue limiting access to traditional financing channels.
The ETF consolidation signals institutional recognition that cannabis investing requires selective stock picking rather than broad sector exposure. With federal rescheduling timeline uncertainty and state market saturation pressures mounting, the three surviving funds must demonstrate differentiated value propositions to retain assets. Current trading volumes and expense ratios suggest further consolidation remains likely unless federal policy changes revive investor appetite for cannabis exposure through diversified fund products.